Antidepressant treatment concerns and recommendations for avoiding adverse events

U.S. Pharmacist

Volumn 39, Issue 11, 2014, Pages 34-36

  Tai, Melissa ^a   Vu, Lamanh ^a   Bostwick, Jolene R ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CIMETIDINE; CITALOPRAM; ESOMEPRAZOLE; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SERTRALINE; TRAMADOL; TRIPTAN DERIVATIVE; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG INDICATION; DRUG SAFETY; HUMAN; PATIENT ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; QT PROLONGATION; RISK REDUCTION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT PLANNING; WITHDRAWAL SYNDROME;

EID: 84924809002     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (28)

1. National Institute of Mental Health. Any mental illness (AMI) among adults. www.nimh.nih.gov/statistics/1ANYDIS_ADULT.shtml. Updated 2012. Accessed May 24, 2014.
2. Harvard Medical School. National comorbidity survey (NCS). Table 1. Lifetime prevalence of DSM-IV/WMH-CIDI disorder by sex and cohort. www.hcp.med.harvard.edu/ncs/ftpdir/NCS-R_Lifetime_Prevalence:Estimates.pdf. Updated 2005. Accessed May 25, 2014.
3. Agency for Healthcare Research and Quality. Reducing and preventing adverse drug events to decrease hospital costs: Research in action. www.ahrq.gov/research/findings/factsheets/errors-safety/aderia/index.html. Updated 2001. Accessed June 2, 2014.
4. Preskorn SH, Flockhart D. 2006 guide to psychiatric drug interactions. Prim Psychiatry. 2006;13:35-64.
5. National Center for Health Statistics (NCHS). Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville, MD: NCHS; 2014.
6. FDA. FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm. Accessed June 2, 2014.
7. FDA. Medication guide: Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions. www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ucm100211.pdf. Accessed June 2, 2014.
8. FDA. FDA drug safety communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. www.fda.gov/drugs/drugsafety/ucm297391.htm. Accessed June 3, 2014.
9. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv. 2011;49:13-16.
10. Zivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170:642-650.
11. Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med. 2012;125:859-868.
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed. Arlington, VA: APA; 2010:1.
13. FDA. Drug development and drug interactions: Table of substrates, inhibitors and inducers. www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed June 3, 2014.
14. Prabhakar D, Balon R. How do SSRIs cause sexual dysfunction? Understanding key mechanisms can help improve patient adherence, prognosis. Curr Psychiatry. 2010;9:30-34.
15. Clayton AH, Balon R. The impact of mental illness and psychotropic medications on sexual functioning: the evidence and management. J Sex Med. 2009;6:1200-1211.
16. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29:259-266.
17. Stimmel GL, Gutierrez MA. Counseling patients about sexual issues. Pharmacotherapy. 2006;26:1608-1615.
18. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997;23:176-194.
19. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
20. How to switch antidepressants. Pharmacist’s Letter/Prescriber’s Letter. 2006;22:220605.
21. World Health Organization (WHO). WHO Expert Committee on Drug Dependence. 35th report. Geneva, Switzerland: WHO; 2003.
22. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120.
23. Nelson EM, Philbrick AM. Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. Ann Pharmacother. 2012;46:1712-1716.
24. FDA. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans). www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085845.htm. Accessed June 3, 2014.
25. Sclar DA, Robison LM, Castillo LV, et al. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache. 2012;52:198-203.
26. Rolan PE. Drug interactions with triptans: which are clinically significant? CNS Drugs. 2012;26:949-957.
27. Oberleitner LM, Tzilos GK, Zumberg KM, Grekin ER. Psychotropic drug use among college students: patterns of use, misuse, and medical monitoring. J Am Coll Health. 2011;59:658-661.
28. Schiff GD, Galanter WL, Duhig J, et al. Principles of conservative prescribing. Arch Intern Med. 2011;171:1433-1440.